Rheumatology Advisor reporter Tori Rodriguez writes on addressing racial disparities in systemic lupus erythematosus (SLE) treatment. 

She interviews Medha Barbhaiya, MD, MPH, rheumatologist at HSS, who explains that SLE is known to disproportionate affect non-white populations in the U.S.

"Future SLE research among racial and ethnic groups should consider the role of diversity in genetic factors, biomarkers, lifestyle and physical activity, other thrombotic risk factors, and socioeconomics among various subpopulations. [Studies should also] evaluate potential gene-environment interactions in relation to outcomes. In addition, the relationship between barriers to healthcare access and long-term outcomes related to SLE need to be further investigated among non-white populations in the United States," says Dr. Barbhaiya.

Read the full article at RheumatologyAdvisor.com.